NCT04620135View on ClinicalTrials.gov

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

July 9, 2021

Study Completion Date

July 30, 2021

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

Netarsudil ophthalmic solution 0.02%

Topical sterile ophthalmic solution Other Name: Rhopressa®

DRUG

Ripasudil hydrochloride hydrate ophthalmic solution 0.4%

Other Name: Glanatec®

Trial Locations (1)

Unknown

Seijo Clinic, Setagaya-Ku

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT04620135 - Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter